Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Chen, Bingni ^a,b   Huang, Kunzhao ^a,b   Ye, Liang ^a,b   Li, Yanqun ^a,b   Zhang, Jiawei ^a,b   Zhang, Jinshun ^a,b   Fan, Xinmin ^a   Liu, Xiaokai ^a,b   Li, Li ^a,b   Sun, Jinxia ^a,b   Du, Jing ^c   Huang, Zhong ^a,b  

^a Shenzhen University   (China)

^b SHENZHEN UNIVERSITY   (China)

^c PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

Author keywords

Ankylosing spondylitis; Interleukin 17; Interleukin 23; Interleukin 37; Interleukin 6; Peripheral blood mononuclear cells; Tumor necrosis factor

Indexed keywords

CYTOKINE; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 37; INTERLEUKIN 6; MESSENGER RNA; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 37; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID; IL37 PROTEIN, HUMAN; INTERLEUKIN 1; RECOMBINANT PROTEIN;

ADULT; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL LEVEL; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LABORATORY TEST; MALE; OSTEOPOROSIS; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; BLOOD; CASE CONTROL STUDY; COMPLICATION; GENETICS; METABOLISM; MONONUCLEAR CELL;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1; LEUKOCYTES, MONONUCLEAR; MALE; OSTEOPOROSIS; RECOMBINANT PROTEINS; RNA, MESSENGER; SPONDYLITIS, ANKYLOSING;

EID: 84924328620     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0394-3     Document Type: Article

References (41)

1. Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology. 2014;53:650-7.
2. López-Larrea C, Sujirachato K, Mehra NK, Chiewsilp P, Isarangkura D, Kanga U, et al. HLA-B27 subtypes in Asian patients with ankylosing spondylitis. Evidence for new associations. Tissue Antigens. 1995;45(3):169-76.
3. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DCO, Sturrock RD. Ankylosing spondylitis and HL-A 27. Lancet. 1973;301:904-7.
4. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379-90.
5. Rasker JJ, Prevo RL, Lanting PJH. Spondylodiscitis in ankylosing spondylitis, inflammation or trauma? Scand J Rheumatol. 1996;25(1):52-7.
6. Taylan A, Sari I, Kozaci DL, Yuksel A, Bilge S, Yildiz Y, et al. Evaluation of the T helper 17 axis in ankylosing spondylitis. Rheumatol Int. 2012;32(8):2511-5.
7. Falkenbach A, Herold M, Wigand R. Interleukin-6 serum concentration in ankylosing spondylitis, a reliable predictor of disease progression in the subsequent year? Rheumatol Int. 2000;19(4):149-51.
8. Gratacós J, Collado A, Filella X, Sanmartí R, Cañete J, Llena J, et al. Serum cytokines(IL-6, TNF-α, IL-1β and IFN-γ) in ankylosing spongdylitis: a close correlation between IL-6 and disease activity and severity. Rheumatology. 1994;33(10):927-31.
9. Wendling D, Cedoz JP, Racadot E, Dumoulin G. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine. 2007;74(3):304-5.
10. Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheumatism. 2009;60(6):1647-56.
11. Jandus C, Bioley G, Rivals JP, Dudler J, Speiser D, Romero P. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheumatism. 2008;58(8):2307-17.
12. Mei Y, Pan F, Gao J, Ge R, Duan Z, Zeng Z, et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol. 2011;30(2):269-73.
13. Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis, a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1705-13.
14. Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis. 2008;67(4):511-7.
15. Rajalingham S, Das S. Antagonizing IL-6 in ankylosing spondylitis, a short review. Inflamm Allergy Drug Targets. 2012;11(4):262-5.
16. Liang Y, Ling J, Zhongyang W, Yanfei Z, Dongsheng H, Yanqun L, et al. IL-37 inhibits the production of inflammatory cytokines in peripheral bloodmononuclear cells of patients with systemic lupus erythematosus, its correlation with disease activity. J Transl Med. 2014;12:69.
17. Zhao PW, Jiang WG, Wang L, Jiang ZY, Shan YX, Jiang YF. Plasma Levels of IL-37 and Correlation with TNF-α, IL-17A, and Disease Activity during DMARD Treatment of Rheumatoid Arthritis. Plos One. 2014;9(5):e95346.
18. Imaeda H, Takahashi K, Fujimoto T, Kasumi E, Ban H, Bamba S, et al. Epithelial expression of interleukin-37b in inflammatory bowel disease. Clin Exp Immunol. 2013;172:410-6.
19. Boraschi D, Lucchesi D, Hainzl S, Leitner M, Maier E, Mangelberger D, et al. IL-37, a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw. 2011;22(3):127-47.
20. Busfield SJ, Comrack CA, Yu G, Chickering TW, Smutko JS, Zhou H, et al. Identification and gene organization of three novel members of the IL-1 family on human chromosome 2. Genomics. 2000;66:213-6.
21. Pan G, Risser P, Mao W, Baldwin DT, Zhong AW, Filvaroff E, et al. IL-1 H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp. Cytokine. 2001;13:1-7.
22. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 2010;11(11):1014-22.
23. Ji Q, Zeng Q, Huang Y, Shi Y, Lin Y, Lu Z, et al. Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome. Mediators Inflamm. 2014;2014:165742.
24. McNamee EN, Masterson JC, Grenz PJMMMA, Collins CB, Nold MF, Nold-Petry C, et al. Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci USA. 2011;108:16711-6.
25. Luo Y, Cai X, Liu S, Wang S, Nold-Petry CA, Nold MF, et al. IL-37 suppresses contact hypersensitivity by inducing tolerogenic dendritic cells. Cytokine. 2013;63(3):283.
26. Song LJ, Qiu F, Fan YC, Ding F, Liu HX, Shu Q, et al. Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus. J Clin Immunol. 2013;33:111-7.
27. Fujita H, Inoue Y, Seto K, Komitsu N, Aihara M. Interleukin-37 is elevated in subjects with atopic dermatitis. J Dermatol Sci. 2013;69(2):173-5.
28. Ballak DB, Li S, van Diepen JA, Moschen AR, Jansen H, Hijmans A, et al. Leo A.B. Joosten, Herbert Tilg, Charles A. Dinarello Mihai G. Nete, Cees J. Tack, Rinke Stienstra. IL-37 protects against obesity-induced inflammation and insulin resistance. Cytokine. 2013;63:245-6.
29. Chen X, Huang J, Chen M, Huang Y, Li N, Liu F, et al. Interleukin-37 attenuates acute lung injury by inhibiting inflammatory response in a mouse CLP model. Gene Therapy Mol Biol. 2013;15:176-84.
30. Li Y, Wang Z, Yu T, Chen B, Zhang J, Huang K, et al. Increased expression of IL-37 in patients with graves' disease and its contribution to suppression of proinflammatory cytokines production in peripheral blood mononuclear cells. PLoS One. 2014;9(9):e107183.
31. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. a proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361-8.
32. Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M. Defining disease activity in ankylosing spondylitis, is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology. 1999;38:878-82.
33. Gratacós J, Collado A, Pons F, Osaba M, Sanmartí R, Roqué M, et al. Significant loss of bone mass in patients with early, active ankylosing spondylitis, a follow up study. Arthritis Rheum. 1999;42(11):2319-24.
34. Geusens P, Vosse D, van der Linden S. Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol. 2007;19(4):335-9.
35. Başkan BM, Doğan YP, Sivas F, Bodur H, Özoran K. The relation between osteoporosis and vitamin D levels and disease activity in ankylosing spondylitis. Rheumatol Int. 2010;30(3):375-81.
36. Bal A, Unlu E, Bahar G, Aydog E, Eksioglu E, Yorgancioglu R. Comparison of serum IL-1β, sIL-2R, IL-6, and TNF-α levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol. 2007;26(2):211-5.
37. Magrey M, Khan MA. Osteoporosis in ankylosing spondylitis. Curr Rheumatol Rep. 2010;12(5):332-6.
38. Wu B, Meng K, Ji Q, Cheng M, Yu K, Zhao X, et al. Interleukin-37 ameliorates myocardial ischaemia/reperfusion injury in mice. Clin Exp Immunol. 2014;176(3):438-51.
39. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suárez-Fariñas M, Fuentes-Duculan J, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204(13):3183-94.
40. Davidson SI, Liu Y, Danoy PA, Wu X, Thomas GP, Jiang L, et al. Association of STAT3 and TNFRSF1A with ankylosing spondylitis in Han Chinese. Ann Rheum Dis. 2011;70(2):289-92.
41. Costello ME, Elewaut D, Kenna TJ, Brown MA. Microbes, the gut and ankylosing spondylitis. Arthritis Res Ther. 2013;15(3):214.